Chemotherapy for primary central nervous system lymphoma

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin lymphoma.
• Chemotherapy, particularly high-dose methotrexate (MTX), is the cornerstone of PCNSL treatment, often combined with radiotherapy.
• Optimal treatment strategies remain debated due to a lack of randomized controlled trials and varying methodologies.

Purpose of the Study:

• To review the principles of chemotherapy use in PCNSL.
• To critically analyze existing literature and recent trials on PCNSL treatment.
• To discuss age-specific treatment paradigms and the development of intensified chemotherapy regimens.

Main Methods:

• Literature review of studies on primary central nervous system lymphoma (PCNSL) treatment.
• Analysis of chemotherapy regimens, including high-dose methotrexate (MTX) and combination therapies.
• Examination of treatment outcomes based on patient age and the role of radiotherapy.

Main Results:

• High-dose methotrexate (MTX) is effective but optimal regimens are controversial.
• Elderly patients (>60 years) may benefit from chemotherapy-only approaches due to radiotherapy neurotoxicity risks.
• Younger patients (<60 years) may face higher relapse rates with standard chemotherapy, prompting research into intensified regimens.

Conclusions:

• Treatment for PCNSL requires age-specific considerations.
• Intensified chemotherapy regimens are being developed to potentially replace radiotherapy and improve outcomes.
• Further research, including randomized trials, is needed to establish optimal PCNSL treatment protocols.